Complementary actions of finerenone and SGLT2-i on renal outcomes?: An urgent need for more information

Nephrology (Carlton). 2022 Dec;27(12):915-916. doi: 10.1111/nep.14124. Epub 2022 Oct 22.

Authors

Eleni Rebelos^{1

2}, Nikolaos Tentolouris³

Affiliations

¹ Turku PET Centre, University of Turku, Turku, Finland.
² Institute of Clinical Physiology, National Research Council (CNR), Pisa, Italy.
³ 1st Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Diabetes Mellitus, Type 2* / diagnosis
Diabetes Mellitus, Type 2* / drug therapy
Humans
Kidney
Mineralocorticoid Receptor Antagonists
Naphthyridines
Renal Insufficiency, Chronic*
Sodium-Glucose Transporter 2

Substances

finerenone
Sodium-Glucose Transporter 2
Naphthyridines
Mineralocorticoid Receptor Antagonists